>

Michael Sneed - Johnson Johnson President

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  President
Mr. Michael E Sneed is the Executive Vice President Global Corporationrationrate Affairs and Chief Communication Officer of the Company. He joined the Company in 1986 as Product Director for Personal Products, a subsidiary of the Company, and gained increased responsibilities in executive positions across the global enterprise. In 2004, Mr. Sneed was appointed Company Group Chairman, Consumer North America, followed by Company Group Chairman, Vision Care Franchise in 2007. In 2012, he became the Vice President, Global Corporationrationrate Affairs and Chief Communications Officer
Age: 58  President Since 2018      
732 214-0332  www.jnj.com
Sneed was appointed Executive Vice President, Global Corporationrationrationrate Affairs and Chief Communications Officer in January 2018, and became a member of the Executive Committee in July 2018, leading the corporation global marketing, communication, design and philanthropy functions.

Michael Sneed Latest Insider Activity

Management Efficiency

The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Ann PowellBristol Myers Squibb Company
2016
Laurie OlsonPfizer
2017
Darren CarrollEli Lilly And Company
2015
Albert BourlaPfizer
2020
Jose BaselgaAstrazeneca PLC
2019
Wayne SwantonAllergan Plc
2017
Rady JohnsonPfizer
2013
Samuel MoedBristol Myers Squibb Company
2012
Sean BohenAstrazeneca PLC
2015
Kathrin JansenPfizer
2015
Laura HamillGilead Sciences
2018
Lidia FonsecaPfizer
2019
Alfonso ZuluetaEli Lilly And Company
2017
Alexander MackenziePfizer
2016
Philippe SchaisonAllergan Plc
2015
Luc DebruyneGlaxoSmithKline PLC
2016
Jan LundbergEli Lilly And Company
2010
A BaileyAllergan Plc
2014
Murdo GordonBristol Myers Squibb Company
2016
Jeffrey SimmonsEli Lilly And Company
2008
Paul HudsonAstrazeneca PLC
2013

Company Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent DirectorView
Jennifer Doudna, Independent DirectorView
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. CommitteeView
William Perez, Independent DirectorView
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication OfficerView
Marillyn Hewson, Independent DirectorView
Jorge Mesquita, Executive Vice President Worldwide Chairman - ConsumerView
Mary Coleman, Independent DirectorView
Michael Ullmann, VP, General Counsel and Member of Executive CommitteeView
Joaquin Duato, Executive Vice President Worldwide Chairman - PharmaceuticalsView
Kathy Wengel, Executive Vice President Chief Global Supply Chain OfficerView
Jennifer Taubert, Executive Vice President - Worldwide Chairman, PharmaceuticalsView
Mary Beckerle, Independent DirectorView
Sandra Peterson, Group Worldwide Chairman and Member of Executive CommitteeView
Scott Davis, DirectorView
Louise Mehrotra, Vice President Investor RelationsView
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical DevicesView
Ronald Williams, Independent DirectorView
Kathryn Wengel, Executive Vice President Chief Global Supply Chain OfficerView
D Davis, Independent DirectorView
Hubert Joly, DirectorView
Anne Mulcahy, Lead Independent DirectorView
Joseph Wolk, Chief Financial Officer, Executive Vice PresidentView
Thibaut Mongon, Executive Vice President Worldwide Chairman, ConsumerView
Ian Davis, Independent DirectorView
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive CommitteeView
Mark McClellan, Independent DirectorView
Charles Prince, Independent DirectorView
Eugene Washington, Independent DirectorView
Dominic Caruso, CFO, VP of Fin. and Member of Executive CommitteeView
Peter Fasolo, Chief Human Resource Officer, Executive Vice PresidentView
Susan Lindquist, Independent DirectorView
Mark Weinberger, DirectorView

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.